Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 6, 2024

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

(Print or Type Responses)

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	1. Name and Address of Reporting Person Hughes Eric A.	2. Issuer Name and Ticker Teva Pharmaceutical In
	(Last) IC/O Teva Pharmaceutical Industries Ltd.	(First)	(Middle)

1. Name and Address of Reporting Person Hughes Eric A.	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024	Officer (give title below) Other (specify below) See "Remarks"
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

l .Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) any	l 2A. Deemed Execution Date, if Code (Month/Day/Year)	13. Transaction or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)		4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership of Indirect Form: Direct (D) Ownership	7. Nature Beneficial
			Code		Amount	(A) or D)	Price		or Indirect (Instr. 4) (1) (Instr. 4)
'Ordinary Shares (1)	03/03/2024		M		24,900	A	(2)	24,900	D
'Ordinary Shares (1)	03/04/2024		ુ(3)		8.045 (4)	D	13.3373	16,855	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
. It . MEEN . PERFERENAMEN . AMERICAN . PARTERRENDERE . MARRESSMENT

1. Title of Derivative Security (Instr. 3)	Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year)	3A. Deemed Execution Date, if Transaction Derivative any (Month/Day/Year) (Instr. 8)	ব Code	( - 1 ) Pronomy accession 1 - 6 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 5. Number of Securities Acquired (A) or Disposed of (D)	(Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount 8. Price of 9. Number of 10. Derivative Derivative of Underlying Security Securities Securities Beneficially (Instr. 3 and 4) (Instr. 5) Owned Following		Ownership of Indirect Form of Derivative Security: Direct (D) or Indirect	11. Nature Beneficial Ownership (Instr. 4)
				Code	(A)	(D)	Date Exercisable Date	Expiration Title		Amount Or Number of Shares		Reported Transaction(s) (Instr. 4)	(1) (Instr. 4)
Restricted Share Units	(2)	03/03/2024		M		24,900	(6)	(6)	Ordinary Shares (1)	24,900	\$ 0	74,701	D
Restricted Share Units	(2)	03/04/2024		A	93,005		(7)	(7)	Ordinary Shares (1)	93,005	\$ 0	93,005	D

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share unit represents a continery share or at the option of the Himan Resources and Compensation Committee, the cast value of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 1065-1 trading plan adopted by the reporting person on November 13, 2023.
• 1. Represents the number of shares required to be sold by the responsibility of gations in comecion with the vesting of the resting of the resting of the restricted share uni
• 1. The price reported in Column 4 is a weles were sold in multiple transactions at prices ranging from S 3.2.5 of \$13.445, including resor undertakes to provide, upon request by the issuer, or any security holder of the issuer, fill information regarding the number of shares soll at each sparate price.
• 1. Restricted share units were granted on March 3, 2024, March 3, 2024, March 3, 2024, March 3, 2026, and 24,90 vessing on March 3, 2027.
• 1. Restricted share units were granted on March 4, 2025, March 4, 2025, March 4, 2025, March 4, 2027, and 23,212 vesting on March 4, 2028,

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Eric Hughes 03/05/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently valid OMB Number.